Abstract: Objective To discuss the efficacy and safety of bevacizumab combined with docetaxel for metastatic breast cancer patients，and observe the efficacy and safety of bevacizumab maintenance therapy in patients with no progression after combination therapy. Methods The whole group was composed with 8 cases，all female，34-62 year-old，and the median age was 53 year-old. All the cases were diagnosed as breast cancer by histopathology after modified radical mastectomy. HER-2 tested by immunohistochemistry were all （+）or （-）. All patients in the group were accepted with bevacizumab（15mg／kg，iv，d1）and docetaxel（75mg／m2，iv，d1）and 3 weeks was a cycle. If no porogression has been detected after 6 cycles of the combination therapy，bevacizumab（15mg/kg, per 3 weeks）was applied alone as maintenance therapy until disease progression or intolerance due to adverse effect. Results All cases could be evaluated，1 case for CR，3 cases for PR，and 4 cases for SD. RR（response rate）was 50％，and DCR（disease control rate）was 100％. Seven cases were received bevacizumab maintenance therapy after 6-9 cycles'combination therapy. The maintenance time was 2-31.3 months；the median maintenance time was 15.3 months. The median progress free survival（PFS）was 22.3 months. Five cases occured grade 3-4 granulocytopenia，in which 2 cases occured fever. Five cases occured nail toxicity，in which 3 cases were grade 1-2，2 cases were occured grade 3. And all these conditions were relieved after the removal of docetaxel.In the 4-36.5 months of the bevacizumab alone maintenance therapy，1 cases occured thrombus （grade 3）, 1 case occured hypertension（grade 2），1 case occured hypertension（grade 3）and 2 cases occured proteinuria（grade 2）. Conclusion Bevacizumab combined with docetaxel and bevacizumab maintained alone can significantly prolong the PFS in advanced HER2 negative breast cancer patients. All cases of the group are well tolerated with long-term bevacizumab treatment.